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AbstrACt
Objectives Use data from the UK Severe Asthma Registry 
(UKSAR) to assess the efficacy and safety of bronchial 
thermoplasty (BT) in routine UK clinical practice and to 
identify characteristics of ‘responders’.
Design Prospective, longitudinal, cohort, multicentre 
registry study.
setting All (11) UK centres performing BT.
Participants and intervention Patients receiving BT in 
the UK between 01/06/2011 and 30/09/2016 who had 
consented to data entry into UKSAR (n=133). Efficacy 
data were available for 86 patients with a BT baseline 
and at least one follow-up record. Safety data were 
available for 131 patients with at least one BT procedure 
record.
Primary and secondary outcome measures Efficacy: 
AQLQ, ACQ, EuroQol, HADS anxiety and HADS depression 
scores, FEV1 (% predicted), rescue steroid courses, 
unscheduled healthcare visits (A&E/Asthma clinic/GP), 
hospital admissions and days lost from work/school. 
Safety: peri-procedural events, device problems and 
any other safety-related findings. Responder analysis: 
differences in baseline characteristics of ‘responders’ 
(≥0.5 increase in AQLQ at 12 months) and ‘non-
responders’.
results Following Bonferroni correction for paired 
comparisons, mean improvement in AQLQ at 12 months 
follow-up compared with BT baseline was statistically 
and clinically significant (0.75, n=28, p=0.0003). Median 
reduction in hospital admissions/year after 24 months 
follow-up was also significant (−1.0, n=26, p<0.0001). 
No deterioration in FEV1 was observed. From 28 patients 
with AQLQ data at BTBL and 12-month follow-up, there 
was some evidence that lower age may predict AQLQ 
improvement. 18.9% (70/370) of procedures and 44.5% 
(57/128) of patients were affected by an adverse event; 
only a minority were considered serious.
Conclusions Improvement in AQLQ is consistent with 
similar findings from clinical trials. Other efficacy outcomes 
demonstrated improving trends without reaching statistical 
significance. Missing follow-up data impacted this 
study but multiple imputation confirmed observed AQLQ 
improvement. The safety review suggested BT is being 
performed safely in the UK.
IntrODuCtIOn
Bronchial thermoplasty (BT) is an estab-
lished non-pharmacological treatment for 
severe asthma. Thermal energy is applied to 
the airway wall to reduce bronchial smooth 
muscle, limiting its ability to contract. It is 
normally delivered in three bronchoscopic 
procedures, approximately 3–4 weeks apart. 
Clinical trials,1–3 and follow-up studies,4–6 
provided early evidence of the efficacy and 
safety of BT but left uncertainty over whether 
the trial results would translate into clinical 
practice.
The need for more evidence from routine 
practice was identified by a Cochrane Review 
in 2014,7 in guidelines jointly published by 
the European Respiratory Society and the 
American Thoracic Society,8 and in the UK 
by the National Institute for Health and Care 
Excellence (NICE) in 2012. NICE reviewed 
BT,9 and recommended collection of safety 
strengths and limitations of this study
 ► The registry captured detailed morbidity and effica-
cy outcomes in the largest series of severe asthma 
patients having bronchial thermoplasty in routine UK 
clinical care, allowing comparison with outcomes 
reported from clinical trials.
 ► Comprehensive coverage of UK clinical practice, 
with almost 100% UK coverage of BT procedures 
being carried out post licence, thus avoiding selec-
tion bias.
 ► Improvement in AQLQ at 12 months assessed by 
paired analysis was confirmed with mixed effects 
modelling. Results from complete case analysis 
were confirmed with multiple imputation to account 
for the effect of missing data.
 ► Limitations include the lack of a comparator group 
and changes over time including prescribed drugs, 
comorbidities, weight and psychological factors 
which may affect the measured outcomes.
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and efficacy outcomes through the UK Severe Asthma 
Registry (UKSAR).10
UKSAR was established in 2006 to collect data on 
patients with severe asthma and, in response to NICE’s 
recommendations, was expanded to incorporate BT. A 
recent study of procedural and short-term safety of BT 
in UK clinical practice using both evidence from UKSAR 
and routine health data11 reported that although the rate 
of adverse events appeared higher than reported from 
clinical trials, only a minority were considered significant 
and that the higher rate may be explained by greater 
severity of asthma in patients being treated in this real-
world setting.
Several case series have been published, reporting on 
BT in clinical practice.12–17 These and an interim analysis 
from a large manufacturer-sponsored study18 all demon-
strate some improvement in quality of life, reductions in 
exacerbations and healthcare resource utilisation and, 
in general, concur with the findings of the clinical trials 
that BT is safe, with none raising any serious concerns. 
However, Thomson and Chanez19 recently reported on 
the contributions of the evidence to date in assessing 
the efficacy of BT in clinical practice and conclude that 
uncertainty remains.
The main aim of this study is to assess the longer term 
efficacy for BT in UK clinical practice. Secondary aims 
are to use experience from clinical practice to identify 
the characteristics of those patients most likely to benefit 
from BT, and to update safety evidence reported previ-
ously. It uses data collected in UKSAR and is one of the 
largest ‘real-world’ observational studies of BT to date, 
with all UK centres performing BT contributing data.
MethODs
The study was designed to follow the recommendations of 
NICE Guidance,9 and also current international efforts to 
improve data collection outside of a clinical trial setting 
for new technologies.20 21
registry design
Safety and efficacy outcomes and the proposed data fields 
to be added to the baseline, procedural and follow-up 
pages in UKSAR were agreed through consultation with 
clinicians in the UK Severe Asthma Network and with the 
support of NICE (see online supplementary table S1). 
Guidance on submitting data to UKSAR was issued to all 
centres providing BT to achieve consistent data capture. 
Modifications to UKSAR to include BT therapy were 
reported in Burn et al.11
Inclusion criteria
Eligible patients were those selected to receive BT in the 
UK between 01/06/2011 and 30/09/2016 with data in 
UKSAR. Patients included in the efficacy study must have 
received BT treatment, had a valid BT baseline (BTBL) 
record and at least one follow-up record.
Patient and public involvement
Patients and the public were not involved in the design 
of this study. However, the findings are presented as 
evidence in the update of NICE interventional guidance 
on Bronchial Thermoplasty.9
registry coverage
During the data collection period, regular contact was 
maintained with the sole manufacturer of the BT device 
to verify that all (11) UK centres performing BT were 
entering data into UKSAR. Regular contact with partic-
ipating centres was maintained to encourage data entry 
and to confirm procedure numbers.
Data extraction
Ethics approval for the registry was provided. Patients 
having BT between June 2011 and September 2016 were 
invited to give fully informed written consent to record 
their information on UKSAR. BTBL, procedure and 
follow-up records in UKSAR at 31 October 2016 were 
extracted for analysis. In accordance with registry infor-
mation governance requirements, the data were provided 
for analysis in anonymised form.
Data cleaning
The follow-ups nearest in time to 6, 12, 24, 36, 48 and 60 
months following the last BT procedure were allocated 
to these follow-up points and the median times to these 
were calculated. Count data for rescue steroid courses, 
unscheduled healthcare visits, hospital admissions and 
days lost from work or school were annualised to compare 
rates before and after BT.
Patient baseline characteristics
Patient baseline characteristics were obtained from 
UKSAR including: age at first BT procedure, gender, 
body mass index (BMI), smoking status, eosinophil count 
(blood), asthma status (including pre-bronchodilator 
forced expiratory volume in 1 s (FEV1) (% predicted) 
and Asthma Quality of Life Questionnaire (AQLQ) 32 
question score22), Asthma Control Questionnaire (ACQ) 
score, EQ-5D-3L descriptive index score, HADS anxiety 
and depression scores, rescue steroid courses, unsched-
uled healthcare usage, hospital admissions, days lost 
from work/school in the previous year, maintenance oral 
steroids (Y/N), oral steroid dose and anti-IgE medication 
(Y/N). Characteristics of age, gender, FEV1 and AQLQ 
score were compared with patients enrolled in clinical 
trials,1–3 and characteristics of those included in the effi-
cacy study were compared with those excluded to check 
for exclusion bias.
efficacy outcomes
The efficacy outcomes considered were AQLQ, ACQ, 
EQ-5D-3L (descriptive index), HADS anxiety and HADS 
depression scores, FEV1 (% predicted), rescue steroid 
courses, unscheduled healthcare visits (A&E/Asthma 
clinic/GP), hospital admissions and days lost from work/
school.
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Outcome measures at BTBL and follow-up points were 
calculated using all available data and compared pair-
wise between BTBL and both 12-month and 24-month 
follow-ups.
Potential confounding factors
Types and doses of medications at BTBL and follow-up 
were not included as outcome measures but were studied 
as potential confounding factors. For the 86 patients 
in the efficacy study, the proportions taking mainte-
nance oral steroids and the median doses at BTBL and 
12-month follow-up were compared. The numbers of 
patients who either remained on oral steroids, off oral 
steroids or started/stopped oral steroids between BTBL 
and 12-month follow-up were also calculated.
A biologic therapy (Omalizumab) may also have been 
prescribed as an anti-IgE medication, and the propor-
tions of patients for whom the anti-IgE registry field was 
ticked at BTBL and 12-month follow-up were compared.
statistical analysis
Mean values were calculated for continuous variables and 
median values for count data. Paired comparisons were 
performed using: two-sided paired t-tests for continuous 
variables; two-sided single sample bootstrap hypothesis 
tests for count data, with data grouped by follow-up time 
points. All variables were checked for normality using 
Shapiro-Wilk tests, and p values obtained by t-tests were 
confirmed using two-sided non-parametric bootstrap 
tests. Comparison of groups used two sample t-tests for 
continuous variables and Wilcoxon rank sum test for 
count data. Comparisons of proportions used proportion 
test and fisher test. The Bonferroni method was used to 
adjust for multiple comparisons. Analysis was performed 
using the ‘R’ statistical programming language with a 
significance level of 95%.
Missing data and additional statistical analyses
To assess the effect of missing data, and potential bias due 
to using available case analysis, additional statistical anal-
yses were performed.
(1) Multiple imputation was applied to study the change 
in AQLQ from BTBL to 12-month follow-up. The R package 
‘MICE’23 was used to impute missing data values in the 
records of the 60 patients having both BTBL and 12-month 
follow-up records. The levels of missing data were examined 
and the number of imputations used in the model set to 100 
(see online supplementary table S2).24–27
Paired t-tests were undertaken on each of the 100 
imputed data sets from which the mean and SD of the 
‘mean change in AQLQ’ were calculated. The rate of 
‘mean change in AQLQ’ <0.5 (not clinically significant) 
and the rate of non-significant p value (<0.05) from the 
100 imputations were also reported.
(2) A linear mixed effects model was used to measure the 
change in AQLQ following BT by using all available obser-
vations without imputation with the R package ‘lmer’.28 This 
class of model accounts for repeated observations (multiple 
follow-ups), tolerates missing values and estimates sizes of 
fixed and random effects separately. The model response 
was AQLQ. There was one fixed effect, time, to test whether 
AQLQ changed over time, and two random effects: of 
patients on intercept (ie, it accounted for different base-
line AQLQ between patients), and of patients on slope (ie. 
it accounted for different patients having different rates 
of change of AQLQ after treatment). The null hypothesis 
of there being no change in AQLQ over time was tested 
using a parametric bootstrap hypothesis test with a gener-
alised likelihood ratio test statistic. CI were estimated using 
bootstrapping.
Comparison of responders with non-responders
Using the AQLQ Minimally Important Clinical Differ-
ence (MCID), a responder was defined as ≥0.5 increase 
in AQLQ score at 12-month follow-up compared with 
BTBL. The baseline characteristics of responders were 
compared with non-responders to assess potential charac-
teristics of those most likely to benefit from BT.
A linear model was constructed with change in AQLQ 
(12-month follow-up – BTBL) as the response variable 
and four covariates: BT1 age, baseline BMI, baseline 
FEV1 (% predicted), baseline eosinophil count (blood). 
Patients with AQLQ observations at BTBL and 12-month 
follow-up were included. All covariates were centred on 
their median values.
To assess the effect of missing covariates, the model was 
repeated using multiple imputation with the records of 
60 patients having BTBL and 12-month follow-up records. 
Median centering was not possible within the multiple 
imputation model.
safety outcomes
UKSAR records added since a previous report of safety 
outcomes11 were reviewed, and peri-procedural events, 
device problems and other potential safety findings were 
tabulated.
results
Data and study participants
Eighty-six patients who received BT treatment had a 
valid BTBL record and at least one follow-up record in 
UKSAR was eligible for inclusion in the efficacy analysis 
(figure 1). The total follow-up time in person-years from 
final BT treatment until the data extraction date of 31 
October 2016 was 253.73 (median 2.85). Data in UKSAR 
for 128 patients having at least one BT procedure were 
available for review of safety outcomes. The total numbers 
of BT records available in UKSAR are shown in online 
supplementary table S3.
baseline characteristics
One hundred and twenty-six patients had a valid 
BTBL record (women: 69.8%; mean age at first BT: 
43.7±12.2 years (n=125); BMI: 31.8±7.5 kg/m2 (n=119); 
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non-smoker/ex-smoker: 98.3% (n=117); FEV1 (% 
predicted): 71.0±21.8 (n=118)).
The baseline characteristics of patients included in the 
efficacy study (n=86) and excluded (n=40) are shown in 
online supplementary table S4. The mean age of those 
included was lower than the excluded group (not signif-
icant after Bonferroni correction). No other significant 
differences were found between the two groups.
Compared with published clinical trials,1–3 patients 
in this efficacy study were on average older, with lower 
FEV1 (% predicted) values (except for the RISA trial) and 
lower AQLQ scores (table 1).
efficacy outcomes
Efficacy outcome measures at BTBL, 12-month and 
24-month follow-up points are shown in table 2 (see 
online supplementary table S5 for data at 6, 36, 48 and 60 
months and online supplementary figure S1). There was 
a clinically significant (>=0.5) improvement in AQLQ at 
12 months. There were also improvements in depression 
scores at 12 months, reduction in healthcare resource 
utilisations at 12 months and reduction in hospital 
admissions at 24 months. After Bonferroni correction, 
only improvement in AQLQ at 12 months and reduc-
tion in hospital admissions at 24 months were statistically 
significant.
Table 3 shows results of paired t-tests following 
multiple imputation analysis for AQLQ score at 12 
months compared with BTBL. 99/100 imputations 
demonstrated a statistically significant mean increase 
in AQLQ at 12 months follow-up; 92/100 imputations 
demonstrated a clinically significant mean increase in 
AQLQ (>=0.5).
Figure 2 shows the AQLQ repeated measures model 
for patients with AQLQ score at BTBL and at least one 
follow-up. From 128 AQLQ observations for 42 patients 
(median follow-up: 572.4 days), values of the fixed effects 
were 3.93 (95% CI 3.55 to 4.43) for baseline AQLQ and 
+0.19 (95% CI 0.00 to 0.36) AQLQ/year for the mean 
annual change of AQLQ after treatment. The random 
effect of baseline AQLQ due to individual patients was 
1.06 (0.75 to 1.37), the random effect of individual 
patients on the annual change of AQLQ was 0.15 (0.02 
to 0.39) AQLQ/year and the residual error SD in the 
model was 0.81 (0.67 to 0.92) AQLQ. The null hypothesis 
of no change in AQLQ over time was rejected at the 5% 
level (p=0.027). Responders (coloured blue) are those 
Table 1 Baseline characteristics of patients with bronchial thermoplasty (BT) in UK Severe Asthma Registry (UKSAR) 
compared with clinical trials
UKSAR AIR2 trial AIR trial RISA trial
Mean age at BT1 (years) 43.7±12.2 (n=125)
Range 21–74
40.7±11.9 (*BT, n=190)
40.6±11.9 (†C, n=98)
39.4±11.2 (BT, n=55)
41.7±11.4 (C, n=54)
39.1±13.0 (BT, n=15)
42.1±12.6 (C, n=17)
% female 70 (n=126) 57 (BT), 61 (C) 56 (BT), 57 (C) 60 (BT), 41(C)
Pre-bronch FEV1
(% predicted)
71.0±21.8 (n=118)
Range: 18–109
77.8±15.7 (BT)
79.7±15.1 (C)
72.7±10.4 (BT)
76.1±9.3 (C)
62.9±12.2 (BT)
66.4±17.8 (C)
AQLQ score‡ 3.66±1.35 (n=81)
Range 1.0–6.81
4.30±1.17 (BT)
4.32±1.21 (C)
5.6±1.1 (BT)
5.7±0.9 (C)
3.96±1.34 (BT)
4.72±1.06 (C)
*BT, subjects receiving BT treatment.
†C, control subjects.
‡A higher AQLQ score represents better quality of life.
AQLQ, Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in 1 s. 
Figure 1 Efficacy study participants. BT, bronchial 
thermoplasty; UKSAR, UK Severe Asthma Registry. 
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with an>=0.5 increase in AQLQ at 12-month follow-up 
compared with BTBL.
There was no significant change in mean values of FEV1 
(% predicted) at 12 or 24 months.
The large number of missing data points and zero 
entries for ‘days lost from work/school’ prevented reli-
able analysis. Table 4 shows all available data for days 
lost from work or school at BTBL (assumed to repre-
sent the preceding 12 months) and 12-month follow-up 
(annualised). Prior to BT, 45.2% of patients (19/42) 
reported losing at least 1 day per year, compared with 
13.5% (5/37) in the year following BT; p=0.005 by 
proportion test.
Potential confounding factors
For 86 patients in the efficacy study, the proportion taking 
maintenance oral steroids at BTBL was 55/85 (64.7%) 
compared with 36/60 (60%) at 12-month follow-up; 
p=0.56. The proportion for whom the anti-IgE registry 
field was ticked (indicating a biologic) at BTBL was 
14/84 (16.7%) compared with 9/54 (16.7%) at 12-month 
follow-up; p=1.0.
Thirty-four patients took maintenance oral steroids 
at both BTBL and 12-month follow-up, 20 patients did 
not take them at either BTBL or 12-month follow-up, 
four patients took them at BTBL but not 12-month 
Table 2 Efficacy: all available data in UKSAR at BTBL, 12-month and 24-month follow-up; paired comparisons of BTBL data 
with outcomes at 12-month and 24-month follow-up (data shown as mean (SD) or median [LQ - UQ])
BTBL (n=86) FU12 (n=60) FU24 (n=34)
BTBL to FU12
(paired)
BTBL to FU24
(paired)
AQLQ score 3.64 (1.26) n=59 4.24 (1.45) n=37 4.40 (1.62) n=19 0.75 n=28 (p=0.0003)* 0.39 n=16 (p=0.148)
EQ-5D score 0.53 (0.38) n=42 0.62 (0.38) n=29 0.65 (0.35) n=18 0.008 n=18 (p=0.909) 0.029 n=13 (p=0.706)
ACQ score 3.28 (1.36) n=49 2.75 (1.34) n=40 3.06 (1.27) n=21 −0.43
n=36 (p=0.083)
−0.26
n=19 (p=0.370)
HADS score (Anxiety) 8.52 (5.54) n=48 6.46 (5.20) n=28 5.28 (5.65) n=18 −1.60
n=20 (p=0.078)
−0.93
n=14 (p=0.216)
HADS score (Depression) 6.46 (5.25) n=48 5.07 (4.50) n=28 4.67 (4.85) n=18 −1.60
n=20 (p=0.047)
−0.57
n=14 (p=0.336)
FEV1 (% predicted) 69.65 (21.71) n=82 74.90 (21.34) n=52 72.71 (21.08) n=31 3.51
n=49 (p=0.152)
2.57
n=30 (p=0.560)
Days from last procedure 
to follow-up
- 381.5
[363.8–408] n=60
738.5
[720.3–775.8] n=34
- -
Rescue steroid courses
(annualised)
4
[2–5.5] n=75
3.1
[1.4–5.8] n=55
1.9
[0.8–4.9](n=29)
−0.26
n=49 (p=0.307)
−1.42
n=27 (p=0.255)
Unscheduled healthcare†
(annualised)
5
[2–6] n=71
3.2
[1.1–5.6] n=52
1.3
[0–2.9]
(n=29)
−0.93
n=47 (p=0.050)
−1.55
n=24 (p=0.062)
Hospital admissions
(annualised)
2
[0–3] n=76
0
[0–1.9] n=55
0
[0–0.6] n=29
−2.0
n=51 (p=0.056)
−1.0
n=26 (p<0.0001)*
*Significant with Bonferroni correction applied for nine paired comparisons (P<0.006) at each follow-up point.
†Includes visits to A&E, GP and asthma clinic.
Table 3 Multiple imputation (MI): paired comparisons of AQLQ at BTBL and 12-month follow-up (FU12) compared with non-
imputed data
AQLQ score (BTBL) AQLQ score (FU12) AQLQ change P value
*Non-imputed data (n=28, mean±SEM) 3.52±0.21 4.27±0.27 0.75±0.07 0.0003
†MI data (n=60) 3.58±0.09 4.24±0.11 0.66±0.13‡ <0.05§
*Paired t-test used to compare 28 patients who had AQLQ measurements at BTBL and FU12.
†60 patients had BTBL and FU12 records which could be used in the multiple imputation. 100 imputations were performed, resulting 
in 100 values for mean AQLQ score at BTBL and 12 month follow-up, and mean change in AQLQ. The means of these values are 
presented in the table. Columns included in the imputation: Hospital, Gender, BT1 Age, BL BMI, BL Smoking Status, BL Eosinophil 
Count (blood), BL FEV1 (% predicted), BL AQLQ, BL Eq_5d, BL ACQ, BL HADS (Anxiety), BL HADS (Depression), BL Rescue Steroid 
Courses, BL Unscheduled Healthcare Visits, BL Hospital Admissions, FU12 Age, FU12 BMI, FU12 Smoking Status, FU12 Eosinophil 
Count (blood), FU12 FEV1 (% predicted), FU12 AQLQ, FU12 Eq_5d, FU12 ACQ, FU12 HADS (Anxiety), FU12 HADS (Depression), 
FU12 Rescue Steroids (annualised), FU12 Unscheduled Healthcare Visits (annualised), FU12 Hospital Admissions (annualised).
‡92/100 imputed datasets had a mean AQLQ change>=0.5.
§99/100 imputed datasets had p<0.05.
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follow-up, two patients did not take them at BTBL but did 
at 12-month follow-up. For 31/34 patients taking main-
tenance oral steroids at BTBL and 12-month follow-up 
(with valid dose information), the median dose (mg/day) 
at BTBL was 25 (IQR:15–30) compared with 20 (IQR:10–
32.5) at 12-month follow-up; p=0.44.
Analysis of responders versus non-responders
18/28 patients with AQLQ data at BTBL and 12-month 
follow-up were classified as responders (defined by 
>=0.5 increase in AQLQ); 10/28 patients were classified 
as non-responders. The baseline characteristics of both 
groups are shown in table 5.
As reported in the pivotal AIR2 trial,1 responders in this 
study also had lower mean baseline AQLQ and higher 
mean baseline ACQ than non-responders; however, 
multivariate analysis showed that the only significant 
predictor of outcome was age at first BT procedure, 
whereby younger patients were more likely to have a 
greater improvement in AQLQ at 12-month follow-up 
(see online supplementary file 2).
Multiple imputation was performed for the 60 patients 
having records at BTBL and 12-month follow-up. 
However, multivariate analysis using the pooled imputed 
data sets just failed to confirm age (p=0.076) as a signif-
icant predictor of improvement in AQLQ at 12-month 
follow-up (see online supplementary file 2).
safety outcomes
There were 370 procedure records in UKSAR for 128 
patients. Table 6 summarises peri-procedural events, 
device problems and potential safety-related events found 
following manual review of all procedure and follow-up 
records. Overall, 18.9% of procedures and 44.5% of 
patients were affected by an adverse event.
Some peri-procedural adverse events, although 
reported in the ‘Unanticipated procedural morbidity’ 
field, could be classed as anticipated. Only a minority of 
procedures were affected by more serious adverse events: 
inflamed airways/bleeding (1), significant desaturation 
(1), lung collapse (one slight) (4), left rib fracture (1), 
metabolic acidosis/lactic acidosis (1), procedure-related 
bradycardia (1), procedure being stopped/early termina-
tion (5).
Nine procedures in eight patients were carried out 
using general anaesthesia. The median number of acti-
vations for all procedures was 34 [min, LQ, UQ, max: 2, 
25, 50.75, 115]. For the procedures carried out under 
general anaesthesia, the median number of activations 
was 38 [min, LQ, UQ, max: 12, 30, 39, 50].
There were two recorded device problems relating to 
catheters; one was changed after two activations when a 
spark was noticed, in another, kinking and infolding were 
reported after treatment of the right upper lobe.
DIsCussIOn
In this ‘real-world’ study of BT, we used clinical registry 
data collected during routine UK clinical practice to 
analyse efficacy and safety outcomes. All UK centres 
performing BT were included and patients in this study 
were not subject to any specific exclusion criteria; their 
suitability for BT was determined on an individual basis 
by a multidisciplinary team. Compared with three clinical 
trials, patients selected to receive BT in clinical practice 
were, on average, older, had lower baseline FEV1 (except 
for RISA trial) and lower AQLQ scores.
Figure 2 AQLQ series for patients with AQLQ data at BT 
baseline and at least one follow-up. Horizontal dashed lines 
show +/-0.5 (clinically significant) change in AQLQ from BT 
baseline. Responders (defined as having>=0.5 increase in 
AQLQ at 12 month follow-up compared with BT baseline) are 
shown in blue. Non-responders are shown in black.
Table 4 Data in UKSAR for days lost from work/school 
(self-reported) at BTBL and 12-month follow-up
Days lost from work/school 
data BTBL* FU12†
Number of patients with 
records
86 60
Number of patients with days 
lost reported
42 37
Patients reporting zero days 23 32
Patients reporting >zero days 19 (45.2%) 5 (13.5%)
Number of days lost reported 406 61
Median [IQR] days lost/person 
(for all patients reporting days 
lost)
0 [0–10] 0 [0–0]
Median [IQR] days lost/
person (for patients 
reporting>zero days lost)
10 [7–15] 13.0 [8.9–15.1]
*Data at BTBL is assumed to represent a 12 month period.
†Data at FU12 is annualised.
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The primary outcome for the AIR2 trial was AQLQ 
at 12 months and it showed an improvement in AQLQ 
of borderline statistical and below clinical significance 
compared with sham. The size of the sham placebo 
response was unprecedented and made interpretation of 
the findings complex. In our study, for 28 patients having 
AQLQ data at BTBL and 12-month follow-up, there was 
a statistically and clinically significant mean improvement 
in AQLQ at 12-month follow-up compared with BTBL. 
The reliability of the improvement in AQLQ reported in 
the AIR2 trial was questioned29–31; therefore, we sought 
further assurance of our results by conducting multiple 
imputation analysis for 60 patients having both BTBL and 
12-month follow-up records. This also showed a statisti-
cally and clinically significant mean improvement in 
AQLQ at 12-month follow-up, consistent with the non-im-
puted data.
The AQLQ MCID of 0.5 was originally calculated for 
patients with mild asthma and, in a severe asthma popu-
lation, may underestimate responders. It is assumed that 
MCID remains the same over the whole range of the 
scale; however, patients with lower baseline AQLQ score 
may perceive an increase of less than 0.5 as meaningful 
compared with patients starting with a higher score. 
Using 0.5 as the MCID, we still found a clinically signifi-
cant mean improvement in AQLQ at 12-month follow-up 
compared with BTBL.
Use of repeated measures analysis for 42 patients having 
AQLQ data at BTBL and at least one follow-up addresses, 
in part, the arbitrary choice of 12 months for conven-
tional paired analysis of change in AQLQ. This approach 
estimated that AQLQ increased by a mean of +0.19/ year 
(which was significantly greater than zero) after treatment, 
assuming it increased linearly. The improvement at 1 year 
predicted by the mean rate (0.19), taking into account all 
follow-up observations, was less than the observed paired 
improvement at 12 months (0.75). This suggests that there 
is still uncertainty over the characteristics of the long-term 
persistence effect of BT beyond 12 months.
For other efficacy outcomes, the data showed trends for 
improvement of similar magnitude to the clinical trials; 
however, the only other statistically significant change 
after Bonferroni correction was the median reduction in 
the annual rate of hospital admissions after 24 months. 
The data indicate a possible reduction in days lost from 
work/school but we report improvements with caution as 
the data includes many zero entries.
Although no significant improvement in FEV1 (% 
predicted) was shown at any follow-up point, a small 
increase in absolute FEV1 was seen with no subsequent 
decline, which is consistent with other reported studies.
Median steroid dose before and after BT was not 
defined as a primary efficacy outcome in our study but is a 
potential confounder. We found no significant change in 
median oral steroid dose at 12-month follow-up compared 
with BTBL for those patients taking oral steroids at both 
time points; however, caution is advised as patients are 
prescribed a variety of medications. Likewise, biologics 
may confound outcomes, but only 16.7% of patients in 
the efficacy study were noted as being on anti-IgE medica-
tion, with the proportion staying constant between BTBL 
and 12-month follow-up.
Table 5 Responder analysis: baseline characteristics of patients who had AQLQ data at BT baseline and 12-month follow-up 
(a responder is defined here as having >=0.5 increase in AQLQ at 12-month follow-up compared with BT baseline). Data shown 
as mean (SD) or median [min, LQ, UQ, max].
Characteristic
Responders
(n=18)
Non-responders
(n=10)
Age at first BT (years) 35.78 (8.7) n=18 50.4 (11.0) n=10
Female (%) 61.1 n=18 60.0 n=10
BMI (kg/m2) 27.7 (5.2) n=17 33.23 (10.7) n=10
Non-smoker/Ex-smoker (%) 100.0 n=17 88.9 n=9
FEV1 (% predicted) 65.9 (22.1) n=18 62.3 (19.1) n=10
Eosinophil count (blood) 0.29 (0.25) n=13 0.51 (0.39) n=8
AQLQ score 3.48 (1.19) n=18 3.59 (1.02) n=10
EQ-5D score 0.54 (0.42) n=11 0.58 (0.39) n=9
ACQ score 3.59 (1.25) n=14 3.07 (0.71) n=9
HADS score (Anxiety) 6.20 (5.53) n=15 10.33 (5.29) n=9
HADS score (Depression) 4.53 (5.40) n=15 7.78 (5.04) n=9
Rescue steroid courses (previous year) 5 [0,2,6,12] n=17 2 [0,1.25,3,7] n=10
Unscheduled healthcare* (previous year) 4.0 [0,1,6,12] n=16 3 [0,2,5,10] n=9
Hospital admissions (previous year) 1.5 [0,0,3.25,10] n=16 0 [0,0,1.5,4] n=10
Days lost from work or school (previous year) 0 [0,1,5,15] n=9 3.5 [0,0,9,15] n=4
*Includes visits to A&E, GP and asthma clinic.
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An exploratory responder analysis with four covariates 
(no interactions) was used to identify patients who might 
potentially benefit from BT, comparing 18 responders 
with 10 non-responders. This showed interesting trends, 
but only younger age was a significant predictor of 
improvement in AQLQ. Multiple imputation failed to 
reproduce this finding.
Peri-procedural and short-term safety outcomes were 
previously reported using data from UKSAR and HES.11 
It was found that 20.4% of procedures in the cohort were 
affected by at least one reported event (including proce-
dural complication, emergency respiratory readmission 
or respiratory A&E attendance (without subsequent 
hospital admission) within 30 days).
This study sought to provide an update using the data 
available in UKSAR. We found that 18.9% of procedures 
and 44.5% of patients were affected by at least one event 
that could be identified from procedure or follow-up 
records. These rates were calculated using all 370 
procedure records with at least the date field completed. 
However, some of these had no further details of the 
procedure so their effect on the rates is unknown. 
Conversely, many peri-procedural adverse events, 
although reported in the ‘Unanticipated procedural 
morbidity’ field, could have been classed as anticipated. 
Including only the more serious or genuinely unantic-
ipated events in the safety analysis would decrease the 
rate of adverse events. Hence, full details of all events 
were included to enable readers to judge the number 
and severity of events.
A strength of this study is the comprehensive coverage 
reported from clinical practice. We achieved almost 
100% UK coverage of BT procedures being carried out 
post licence as confirmed by the sole manufacturer of the 
BT device. Data were obtained from centres performing 
lower numbers of procedures and those that had previ-
ously participated in the clinical trials, thus avoiding any 
selection bias.
Table 6 Safety
Peri-procedural events
Number of procedures 
affected (n=370*)
Number of patients affected 
(n=128†)
Events preventing treatment completion
(Excessive cough, discomfort and pain/bronchospasm)
5 5
Infection 8 8
Exacerbation 13 11
Asthma-related symptoms
(Drop in FEV1, wheeze, shortness of breath, low Sao2)
24 19
Procedure related symptoms
(Bronchospasm, dry cough, chest twinges/tightness/discomfort/pain)
20 16
Other (Left rib fracture) 1 1
Other (Metabolic acidosis) 1 1
Other (Inflamed airways, bleeding medial basal) 1 1
Other (Lung collapse, one slight) 4 4
Other (Procedure-related bradycardia) 1 1
Additional reports
  Device-related (catheters needed replacement) 2 2
  Prolonged stay (>=7 days) with no reason given) 3 2
  A&E attendance with no details given 1 1
  Airway tracheomalacia reported 2 2
  BT3 postponed 2 months due to inflamed airways & pain 1 1
Three procedures not able to be performed: ‡
  BT1 only - 2
  BT1 and BT2 only - 2
CT scan reports (up to 6 month follow-up)
(From 24 CT scan reports in 21 patients)
Central bronchiectasis - 1
Other bronchiectasis - 2
Total events 87 -
Unique procedures/patients affected 70 (18.9%) 57 (44.5%)
*370 procedures in total were entered with a date in UKSAR, but some had minimal procedural information recorded.
†Three patients were excluded as they had no procedure records entered in UKSAR.
‡In addition, four patients hadn’t completed all 3 procedures at 30/09/2016.
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We used more than one statistical method to analyse 
the change in AQLQ, and the results were consistent in 
each.
A limitation of this study is the lack of comparator group 
so the observed improvements may be due to placebo 
effect. Additionally, over time, various factors affect the 
measured outcomes; patients are prescribed different 
drugs after BT, and comorbidities, weight change, and 
psychological factors may all affect outcomes. We did not 
study paired data beyond 24-month follow-up as there 
were diminishing numbers of follow-up records available 
for analysis and other confounding factors may become 
more significant.
Despite the recommendation in NICE Guidance for 
data collection, the biggest limitation is the poor follow-up 
data completion, resulting in only a small number of 
patients with data sets available for follow-up analysis. 
While we recognise that missing data limit generalisability, 
we performed multiple imputation analysis to address 
this and the imputation model did support the observed 
improvement in AQLQ score at 12-month follow-up. 
Improvements in several other outcome measures which 
were non-significant after correcting for multiple testing 
suggest that there is still a need to capture more longer-
term outcome information to fully understand the effec-
tiveness of BT.
COnClusIOns
In summary, this paper presents outcomes from the 
largest UK 'real-world' study of bronchial thermoplasty 
to date. The mean improvement in AQLQ at 12 months 
compared with BTBL is consistent with similar findings 
from clinical trials. No deterioration in FEV1 (% predicted) 
was observed following BT and there was a significant 
reduction in hospital admissions at 24-month follow-up. 
However, improvements were not seen in all patients and 
an exploration of the characteristics of ‘responders’ to BT 
could only identify age as a possible predictor of outcome. 
Current and future studies looking into factors which 
determine those who respond well to BT will be crucial 
to informing patient selection. Continued data collection 
would also help to understand whether the improvement 
in AQLQ observed for some patients is maintained over 
a longer period. Although a health economic analysis was 
beyond the scope of this study, the improvement in QoL 
and reduction in healthcare usage would suggest that BT 
may bring cost savings.
Of the adverse events recorded, only a minority were 
considered significant by the treating clinician. It appears 
that BT is being carried out safely in the UK; however, 
long-term safety should continue to be monitored and 
the decision to select a patient for BT should continue 
to lie with a multidisciplinary team who can assess their 
history and suitability for the procedure.
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